Drug intelligence / Profile preview

SA-702

Development stage: Preclinical
Lead developer: Cleveland BioLabs

Overview

**SA-702** is an investigational preclinical drug candidate listed in Cleveland BioLabs' pipeline for **addiction, infection, and cancer**. Publicly available pipeline materials identify it only by the code name SA-702 and do not disclose a molecular target, modality, formulation, route, or detailed mechanism of action. Based on the available company pipeline information, it appears to be an early-stage proprietary therapeutic program being advanced by Cleveland BioLabs, but its pharmacology remains undisclosed in the source material.

Targets

TLR5

Beyond the preview

Go deeper on SA-702.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SA-702.

Explore the full profile